Peptides investigated for intestinal repair and gut barrier function — ranked by research depth.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Gut-health peptides are dominated by BPC-157, which was originally isolated from human gastric juice. Most research is preclinical and focused on cytoprotection. Human clinical evidence for chronic gut conditions remains limited.
How we ranked: Ordered by: (1) research volume in GI models, (2) mechanism, (3) any human data.
Body Protective Compound 157 was derived from a sequence in human gastric juice. Animal models demonstrate protection against NSAID-induced ulcers, colitis in chemical models, and gastric mucosal repair. Human IBD trials remain preliminary.
Immunomodulatory peptide with clinical experience in hepatitis and immune dysfunction. Indirect gut-health rationale via immune regulation rather than direct mucosal action.
No. BPC-157 is not FDA approved for any indication. It was placed on the Category 2 list in late 2023, prohibiting 503A compounding pharmacies from producing it for human use.
No controlled human trial has established this. The strong preclinical case for intestinal barrier support has not yet been translated into adequate human evidence.
Oral BPC-157 has been studied in animal models. Bioavailability and clinical efficacy of oral formulations in humans is not established in controlled trials.